B tier · viable
Decades of use and a licensed ovulation-induction indication support it, but modern head-to-head randomised data place it second to letrozole in PCOS and its use in men remains explicitly outside the approved label.
clomifene
Clomifene is a mixed estrogen receptor agonist-antagonist licensed for ovulation induction in anovulatory women desiring pregnancy, an indication supported by long clinical experience and multiple randomised comparisons. Its widely discussed use in men is off-label, and the manufacturer's own labelling states it is not recommended in males.
the explanation
Clomifene tricks the brain into thinking estrogen levels are low, which increases the hormone signals that drive the ovaries or testes. It is an approved fertility medicine for women, but it is not approved for men and can cause vision problems and, in women, dangerous ovarian overstimulation.
regulatory status
Approved prescription medicine
FDA-approved for the treatment of ovulatory dysfunction in women desiring pregnancy. US labelling explicitly states use in males is not recommended and notes reports of testicular tumours and gynecomastia in men who used it. On the WHO Model List of Essential Medicines for its fertility indication.
how it works · proposed mechanism
Clomifene blocks hypothalamic and pituitary estrogen receptors, removing the negative feedback that restrains gonadotropin output.
Hypothalamic feedback blockade
By occupying estrogen receptors in the hypothalamus, clomifene prevents circulating estradiol from signalling sufficiency. The hypothalamus responds by increasing GnRH pulse frequency and amplitude.
Downstream gonadotropin rise
Increased GnRH drive raises pituitary secretion of LH and FSH. In anovulatory women this can recruit a dominant follicle and trigger ovulation.
Two isomers, two profiles
Commercial clomifene contains enclomifene and zuclomifene, which differ in receptor behaviour and half-life. Zuclomifene persists far longer and is thought to contribute to residual anti-estrogenic effects on cervical mucus and endometrium.
what’s reported
evidence shape
30 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Clomifene's approved evidence base concerns ovulation induction in women trying to conceive, an endpoint with a clear, measurable outcome and short defined treatment cycles under specialist supervision. That data says nothing about long-term unsupervised use in men as a steroid ancillary, where the labelling actively warns against male use, there are no randomised outcome trials, and the persistent zuclomifene isomer accumulates without any monitoring for the visual and gonadal effects the label documents.
key published findings
- Human trial (PPCOS II, Legro et al., NEJM 2014, n=750 women with PCOS): letrozole produced a live birth rate of 27.5% versus 19.1% for clomifene (rate ratio 1.44, P=0.0007), with ovulation rates significantly higher for letrozole at each monthly visit from the second visit onward.
- Human trial (PPCOS II adverse events): hot flushes occurred in 33% of clomifene recipients versus 20.3% of letrozole recipients, while letrozole produced more fatigue (21.7% vs 14.9%) and dizziness (12.3% vs 7.6%), with no appreciable difference in serious adverse events.
- Regulatory data (US prescribing information, pooled clinical studies): ovarian enlargement occurred in 13.6%, vasomotor flushes in 10.4%, and visual symptoms including blurred vision in 1.5% of treated patients.
- Regulatory data (US prescribing information): the multiple pregnancy rate was 7.98%, comprising 6.9% twin, 0.5% triplet, 0.3% quadruplet and 0.1% quintuplet pregnancies.
- Regulatory data (US prescribing information): prolonged use may increase the risk of borderline or invasive ovarian tumours, and the label states that use in males is not recommended, citing reports of testicular tumours and gynecomastia.
limitations of the evidence
- The randomised evidence base is almost entirely in anovulatory women pursuing pregnancy, with short treatment cycles and defined reproductive endpoints; long-term continuous exposure is not what was studied.
- Modern head-to-head randomised data favour letrozole for live birth in PCOS, so clomifene is no longer the preferred first-line option in that population.
- Male use is off-label, explicitly discouraged by the US label, and lacks randomised long-term efficacy or safety outcome data.
documented safety signals
- Visual disturbances reported in approximately 1.5% of patients, including blurred vision, scotomata, phosphenes, floaters and photophobia; the label advises discontinuation and ophthalmological evaluation, and cases of persistent visual symptoms and presumed optic neuropathy have been published.
- Ovarian hyperstimulation syndrome, a potentially serious complication that can involve ascites, pleural effusion, haemoconcentration, thromboembolism and, in severe cases, death.
- Ovarian enlargement reported in 13.6% of treated patients, occasionally with cyst formation and torsion.
- Multiple gestation in approximately 8% of pregnancies, with associated obstetric and neonatal risk.
- Possible increased risk of borderline or invasive ovarian tumours with prolonged use, per the US label, though causality is not established.
- US labelling explicitly states that use in males is not recommended, and notes reports of testicular tumours and gynecomastia in males who have used it.
- Vasomotor flushes in approximately 10% of patients, plus abdominal discomfort, nausea, breast tenderness, headache and mood changes.
- Anti-estrogenic effects on cervical mucus and endometrial thickness that can work against the fertility outcome the drug is prescribed to achieve.
- Contraindicated in pregnancy, in undiagnosed abnormal uterine bleeding, in ovarian cysts not due to PCOS, and in significant liver disease.
- Reported association with abnormal uterine bleeding and, rarely, thromboembolic events and seizure activity in susceptible individuals.
identity
| full name | Clomifene citrate (clomiphene citrate) |
| category | Ancillary & Endocrine |
| modality | small molecule |
| formula | C26H28ClNO |
| molar mass | 405.97 g/mol |
| cas | 911-45-5 |
| half-life | Approximately 4-7 days for the parent compound; hydroxylated metabolites approximately 13-37 hours |
laboratory handling
| storage | Tablets stored at controlled room temperature, approximately 20-25 degrees C, protected from heat, light and excessive humidity in the manufacturer's container. |
| solubility | Clomifene citrate is a white to pale yellow crystalline powder, slightly soluble in water and soluble in ethanol and methanol. |
| co-studied with | Frequently discussed online as a gonadotropin-restoring agent after androgen use, but the approved evidence base concerns ovulation induction in women only, the US label advises against male use, and no randomised trial has evaluated it in the steroid-recovery context. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedUS prescribing information · 2024 · official
FDA Drugs@FDA · 2012 · official
Wikipedia drug monograph (referenced compilation) · 2026 · review
New England Journal of Medicine · 2014 · randomized
PubMed Central case report · 2021 · observational
others in Ancillary & Endocrine